AML1/RUNX1 is a critical transcription factor in hematopoietic cell differentiation and proliferation. From the AML1 gene, at least three isoforms, AML1a, AML1b and AML1c, are produced through alternative splicing. AML1a interferes with the function of AML1b/1c, which are often called AML1. In this study, we found a higher expression level of AML1a in acute lymphoblastic leukemia and acute myeloid leukemia (AML)-M2 patients in comparison to the controls. Additionally, AML1a represses transcription of promoter of macrophage colony-stimulating factor receptor mediated by AML1b, indicating that AML1a antagonized the effect of AML1b. To investigate the role of AML1a in hematopoiesis and leukemogenesis in vivo, murine bone marrow mononuclear cells were transduced with AML1a and then transplanted into lethally irradiated mice, which developed lymphoblastic leukemia after transplantation. Taken together, these results indicate that overexpression of AML1a may be an important contributing factor to leukemogenesis.
Introduction
AML1, also known as RUNX1, PEBP2aB or CBFa2, is a transcription factor that plays a crucial role in the proliferation and differentiation of hematopoietic cells. AML1 has a DNA binding domain, known as the runt homology domain (RHD), and a transactivation domain that binds to and regulates target genes, respectively. 1 AML1 are affected by chromosomal translocations found in human leukemia, including t(8;21), t(3;21) and t(12;21). [2] [3] [4] The t(8;21) is most frequent chromosomal translocation in acute myeloid leukemia (AML), and it joins AML1 to ETO, resulting in the formation of AML1-ETO fusion gene in which AML1 retains RHD, but lacks the transactivation domain. 5, 6 The lack of transactivational domain is supposed to be the event that triggers leukemogenesis. 6 AML1 is essential for hematopoiesis in early development as well as in adulthood. AML1-null embryos die typically around E12.5 because of a lack of fetal liver hematopoiesis and hemorrhage in the central nervous system. 7, 8 Loss of AML1 function in adulthood leads to a number of disturbance in hematopoiesis, including retarded megakaryocytic maturation and impaired T-and B-lymphocytic differentiation. 9 In addition, it has been proved that AML1-deficient cells are susceptible to malignant transformation. 10 AML1 regulates promoters or enhancers of many target genes, including interleukin 3, 11 myeloperoxidase, 12 neutrophil elastase, 13 granulocyte-macrophage colony-stimulating factor (GM-CSF), 14 macrophage colony-stimulating factor receptor (M-CSFR) 15, 16 and T-cell antigen receptor subunits (TCRs). 5, 17 RHD is near the N terminus and contains approximately 128 amino-acid residues. 18, 19 Affinity of AML1 for its target DNA sequences increases significantly upon heterodimerization with CBFb. [20] [21] [22] At least three alternative splice variants of the AML1 gene (AML1a, AML1b and AML1c) have been identified to date. 1 The proteins encoded by AML1b and AML1c have an RHD in the N terminus and a transactivation domain in the C terminus. 1 In contrast, the protein encoded by AML1a has a RHD but lacks the transactivation domain. As such, the function of AML1 is believed to be mediated by AML1b and AML1c which are considered to have the same function. 1 Experiments using transient transfection have demonstrated that AML1b, but not AML1a, transactivated TCRs 5,17 and GM-CSF. 23 AML1a has no transactivational function by itself, but inhibits the transcriptional activity of AML1b by competing for the DNA sequence of target genes with a higher affinity. 6 Overexpression of AML1a inhibits the myeloid terminal differentiation of the myeloid precursor lineage 32Dcl3 induced by G-CSF. Recent evidence showed that the overexpressed AML1a is higher in patients with AML than the normal controls. 6 Accordingly, we hypothesize that AML1a, similar to the leukemia-associated fusion proteins, perturbs the normal function of AML1, and maybe contribute to leukemogenesis.
In this study, we first examined the expression level of AML1a in bone marrow mononuclear cells (BMMNCs) of acute leukemia (AL) patients. Results indicated that AML1a expression level in acute lymphoblastic leukemia (ALL) and subgroup of AML (AML-M2) patients was significantly higher than that in healthy donors. We further analyze the effects of AML1a and AML1b on the transactivity by using a luciferase reporter plasmid containing M-CSFR promoter. Result demonstrated that AML1a competes with AML1b to inhibit the transcription of M-CSFR. Finally the in vivo effect of AML1a was explored by transplantation of AML1a expressing BMMNCs into lethally irradiated mice. Of 12 mice, 9 developed lymphoid leukemia between 16 and 45 weeks after transplantation. These results demonstrated: (1) AML1a is a functional AML1 'antagonist'; (2) overexpression of AML1a may serve as a critical oncogenic event to promote leukemogenesis.
Materials and methods

Patients and cell lines
A total of 77 patients with de novo AL from our hospital and 7 healthy donors were studied after giving informed consent. Diagnosis and classification of the leukemia were made on the basis of Morphology-Immunology-Cytogenetics-Molecular biology typing standard using the French-American-British system. 24, 25 CV-1, NIH 3T3 and 293T cell lines were maintained in Dulbecco's modified Eagle medium supplemented with 10% fetal bovine serum (FBS). U937 cell line was maintained in RPMI 1640 supplemented with 10% FBS.
RNA isolation and reverse transcriptase polymerase chain reaction
Described in the Supplementary Information. 
Construction of plasmids
Southern blot analysis and genomic DNA polymerase chain reaction
Genomic DNA from spleen cells of the leukemic mice was isolated. Genomic DNA (10 mg) was digested with BglII or XhoI, electrophoresed on 1% agarose gel, transferred onto Hybond N þ membrane (Amersham, Piscataway, NJ, USA), and hybridized with a digoxigenin-dUTP-labeled 0.5 kb (kilobase) NcoI fragment corresponding yellow fluorescent protein (YFP) or BamHI-NotI fragment corresponding AML1a as probe. Southern blot analysis was performed with Dig high prime DNA labeling and detection starter kit II (Roche Diagnostics, Mannheim, Germany). The washed membrane was exposed to X-ray film. For genomic DNA PCR, 0.2 mg of the DNA was used as a template in a 25 ml reaction, with primers 5 0 -CACTATAGG GAGACCCAAG-3 0 and 5 0 -CTATTCTATAGTGTCACCT-3 0 for the human AML1a gene. The PCR reaction was performed for 30 cycles at 94 1C for 45 s, 54 1C for 45 s and 72 1C for 45 s, followed by 72 1C for 2 min.
Western blot analysis
We performed protein lysate preparation and western blotting as previously described. 26 Anti-FLAG monoclonal antibody and anti-b-actin antibody were purchased from Sigma. The blots were visualized by chemiluminescence (ECL; Amersham, Freiburg, Germany).
Flow cytometry of mouse cells
For lineage marker analysis, cells (1 Â 10 6 ) were incubated with monoclonal antibodies against Sca-1, c-Kit, Gr-1, Mac-1, Ter119, B220, CD19, Thy1.2, CD3, CD4, CD8 or their isotype controls (Biolegend, San Diego, CA, USA). The cells were then washed and applied for analysis on a FACSCalibur flow cytometer (Becton Dickinson, San Jose, CA, USA).
Hematological and histological analysis
Peripheral blood (PB) smears and bone marrow (BM) cytospin slides were stained with Wright-Giemsa staining solution. Tissue samples were fixed with 10% phosphate-buffered formalin and embedded in paraffin. Sections were stained with hematoxylin and eosin and observed under a light microscope.
Statistical methods
For statistical analysis, survival curves were produced using the Kaplan-Meier estimates, group distributions were compared parametrically using the Student's t-test and group distributions were compared non-parametrically using the Mann-Whitney U-test or w 2 -test.
Results
Expression of AML1 isoform in AL
BM samples from 77 de novo AL patients, including 51 of AML, 21 of ALL and 5 of biphenotypic acute leukemia (BAL), and 7 healthy donors were analyzed by semiquantitative reverse transcriptase-PCR (RT-PCR). AML1a expression in AL cells is not associated with gender, age, initial white blood cell count and median percentage of BM blast cells (Supplementary Table  1 ). Expression level of AML1a in 21 ALL patients was significantly higher than that of the healthy controls (Po0.05; Figure 1a ). However, the expression of AML1a in the healthy controls did not differ significantly from that in AML or BAL ( Figure 1a) . Furthermore, we analyzed the expression levels of AML1a in different subtypes of AML cases according to FAB phenotype. The result showed that the expression level of AML1a did elevate significantly in M2 patients without t(8;21) translocation compared with that of the healthy controls (Po0.05; Figure 1b ). However, there was no significant difference was observed in AML1a expression level between other subtypes of AML and healthy control. The data suggest that overexpression of AML1a might play an important role in leukemogenesis.
Effects of AML1 transcripts on the transactivation of M-CSFR gene
As AML1 is a transcription factor and AML1a is overexpressed in ALL and AML-M2 patients, next we analyzed the effects of AML1a on transcription of AML1 target gene. The CV-1 cells were transfected with a plasmid expressing AML1a or AML1b.
At 36 h after transfection, activity of the luciferase reporter gene was analyzed by luminometer. As shown in Figure 2 , the transcriptional activity of M-CSFR promoter was activated by AML1b ( Figure 2a ) in a dose-dependant manner, but not by AML1a (Figure 2b) . A 3.8-fold increase in luciferase activity was observed in cells transfected with pCMV5-AML1b at a dose of 0.2 mg, but not in cells transfected with pcDNA3-FLAG-AML1a
AML1 isoform induces leukemia X Liu et al at the same dose (Figures 2a and b) . The difference between the two isoforms was statistically significant (Po0.01). As shown in Figure 2c , transactivation of M-CSFR mediated by AML1b was abrogated by cotransfection with AML1a in a dose-dependent manner. The aforementioned effects were completely absent in cells with mutant M-CSFR promoter in which AML1 binding sequence was disrupted (Figure 2d ), indicating the specificity of the findings.
AML1a induces the development of lymphoblastic leukemia
As AML1a could interfere the transcription regulation mediated by full length of AML1, AML1b. Overexpression of AML1a in hematopoietic cells may result in impairment of hematopoiesis or development of leukemia. To address this issue, we analyzed the effects of AML1a in vivo. BMMNCs infected with the retroviral vector murine stem cell virus (MSCV) expressing a FLAG-AML1a fusion protein and a YFP ( Figure 3a) were inoculated into the lethally irradiated female C57 BL/6J mice. BMMNCs infected with the vector expressing YFP only were used as control. Number of transplanted YFP-positive cells in both groups was approximately 30 000 per mouse. The expression of the fusion proteins was confirmed by western blot (data not shown). Number of YFP-positive cells in PB as well as general health condition of the mice was surveyed closely. Of the 12 mice in the AML1a group, 9 developed leukemia at 3-11 months (Figure 3b ; Table 1 ). Signs of cachexia, 
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such as loss of body weight in these mice coincided with a rapid rise of YFP-positive cells from an initial level of 2-3% to 10-25% in PB. The median survival time of the mice in the AML1a group was 258 days. Autopsy of these mice revealed splenomegaly and hepatomegaly (Figures 3c and d) , sometimes with thymoma and lymph node enlargement. BM, spleen, lung, liver, kidney and thymus were infiltrated with leukemia cells (Figures 3e-i) .
A Southern blot analysis by using digoxigenin-dUTP-labeled YFP probe showed that most of the integration of AML1a retrovirus in leukemic cells was monoclonal (Figures 3a and 4a) . Genomic PCR and Southern blot analysis by using digoxigenindUTP-labeled AML1a probe were performed to verify the integration of AML1a in the genome of leukemic spleen cells (Figures 3a, 4a and b) . RT-PCR was performed to analyze the expression of AML1a in spleen cells of mice (Figure 4c ). The Wright-Giemsa-stained peripheral blood (PB) (e) and bone marrow (BM) (f) cytospin from representative leukemic AML1a mice ( Â 1000) and hematoxylin and eosin (H&E) staining of involved organs (g-i) ( Â 400). The normal framework was destroyed and infiltrated by large number of tumor cells in BM (g), spleen (h) and thymus (i).
293T cells transfected with plasmid pMSCV-FLAG-AML1a-IRES-YFP was used as a positive control. As indicated in Figure 4d , the FLAG-AML1a fusion protein was clearly detected in the spleen sample of the AML1a leukemic mice. Flow cytometry showed that 30-60% of the BMMNCs from AML1a group were positive for YFP, in comparison to 8-15% in the control group. A further analysis revealed that there are two different phenotypes of T-lymphoblastic leukemia in mice with leukemia (Table 1) . One was Sca- Figure 5a ), the other was
To assess transplantability of the leukemia, spleen cells from each leukemic mouse were inoculated into four naive mice through the tail vein. All mice rapidly developed lymphoblastic leukemia, with an average latency of 47 days (data not shown).
Discussion
In this study, we found that AML1a is overexpressed in patients of ALL and AML-M2. A previous study using a qualitative assay for AML1a mRNA 6 showed that AML1a could be detected in half of the patients with AML, whereas almost no expression of AML1a could be detected in normal subjects. Here, we used a semiquantitative assay to expand the investigation in more subjects. Surprisingly, we did not find a significant difference in the expression of AML1a between all subtypes AML patients except AML-M2 and the healthy donors. Instead, a significant difference was found between ALL patients and the control. However, the number of patients and healthy controls was limited in this study, further investigation should be performed to expand the sample number to obtain more accurate expression levels of AML1a in patients.
AML1-ETO, as a dominant negative protein, blocks transactivation of the GM-CSF promoter mediated by AML1b.
23
AML1-ETO constitutes the first hit by blocking the differentiation of hematopoietic stem cell (HSC). Myeloid leukemia develops when the second hit occurs. 26 Initially, we suppose that, similar to AML1-ETO, AML1a lacks transcriptional activity, but binds to target genes with higher affinity than AML1b, 6 and thus may contribute to leukemogenesis. It would influence myeloid differentiation and play a certain role in development of leukemia, so we choose M-CSFR as the target gene of AML1 to study. In our experiments, activity of the M-CSFR promoter was dose-dependently transactivated by AML1b, but not by AML1a. More importantly, AML1a interfered with the transactivational effect of AML1b in a dose-dependent manner. A previous study also demonstrated that such an inhibitory effect by AML1a could be reversed by the overexpression of AML1b suggesting a competitive mechanism.
In our experiments in vivo, 75% of the recipient mice after transplantation of AML1a retrovirus-infected BMMNCs developed leukemia. In comparison with the results in patients, the leukemia cells in these mice were only lymphoblastic, which is in accord with the evidence that AML1 is indeed involved in the regulation of T-cell-specific gene expression. 27 In addition, the investigation of the AML1 transcription suggests that AML1 may be critically involved in differentiation of lymphoid precursors in adult hematopoiesis. 28 Moreover, transition of the T cells from the CD4 À CD8 À (DN) to the CD4 þ CD8 þ (DP) phenotype is impaired in transgenic mice bearing a truncated, dominant interfering form of AML1 (runt). 29 Consistent with the findings by 
AML1 isoform induces leukemia X Liu et al
Sato et al., 30 we found that overexpression of AML1a may also influence DN or DP phase of T cells. Finally, AML1 deficiency has been reported to predispose mice to T-lymphoblastic lymphoma. 10 Our data suggest that AML1a overexpression may be a critical event in the development of leukemia. However, the overexpression of AML1a alone may not be sufficient for leukemogenesis. First, not all AML1a-transduced mice developed leukemia. Second, leukemia developed after a relatively long period, suggesting that additional mutations or hits may be required. The monoclonal integration of AML1a retrovirus in leukemic cells may also support this hypothesis. Two different immunophenotypes of lymphoid leukemia were observed in leukemic mice, indicating that some mutations occurred in different development and differentiation stages of HSC. A recent study by Tsuzuki et al. suggested that AML1a may enhance the self-renewal capacity of HSC. Based on the findings that the overexpression of AML1a increases the engraftment potential of hematopoietic stem and progenitor cells, it is suggested that AML1a may be applied in hematopoietic cell transplantation to expand the number of cells. 31 However, results from this study provided experimental evidence that the safety to utilize AML1a in transplantation was called in question before a thorough investigation.
In conclusion, our study indicated that AML1a may play a critical role in leukemogenesis, especially in the development of lymphoid leukemia. In addition, lymphoblastic leukemia model established in this study may serve as a valuable tool for future studies. 
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